Skip to main content
Premium Trial:

Request an Annual Quote

ZaBeCor, Biothorpe Pharmaceuticals, Rosetta Genomics, Isis Pharmaceuticals, Alnylam Pharmaceuticals, Regulus Therapeutics, MDRNA, Nasdaq Stock Exchange

Premium
ZaBeCor Forms Subsidiary to Focus on Cancer
 
Private RNAi drug developer ZaBeCor said this week that it has formed a subsidiary called Biothorpe Pharmaceuticals to develop siRNAs, antisense compounds, and other molecular technologies as treatments for cancer.
 
ZaBeCor was founded in 2002 using technology licensed from the University of Pennsylvania, including the use of siRNAs against an intracellular kinase called Syk that is associated with numerous inflammatory responses (see RNAi News, 6/8/2006).
 
According to the company, Syk kinase is also required for cellular proliferation in several cancers. As such, the company intends to license its intellectual property to Biothorpe for use in developing treatments for acute myelogenous leukemia, B cell lymphoma, and chronic lymphocytic leukemia.
 
ZaBeCor will continue to focus on inflammatory disorders, it added.
 

 
Rosetta Liver Cancer Partnership with Isis Transferred to Regulus
 
Rosetta Genomics this week announced that its collaboration with Isis Pharmaceuticals to develop a miRNA-targeting treatment for liver cancer has been transferred to Regulus Therapeutics, a miRNA joint venture between Isis and Alnylam Pharmaceuticals.
 
According to Rosetta, the arrangement will continue under the same terms and conditions of the original deal (see RNAi News, 2/23/2006).
 

 
MDRNA Stock Fails to Meet Nasdaq Listing Requirement
 
MDRNA said this week that it has received a notice from the Nasdaq Stock Market that its stock has failed to comply with the exchange’s minimum bid price requirement after trading below $1 per share for 30 consecutive days.
 
As a result, the shares could be delisted.
 
The company said it has 180 days to regain compliance, which requires that the stock trade at or above the $1 for a minimum of 10 consecutive days.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.